ID27002A - Penghambat-penghambat kaspase - Google Patents

Penghambat-penghambat kaspase

Info

Publication number
ID27002A
ID27002A IDW20002100A ID20002100A ID27002A ID 27002 A ID27002 A ID 27002A ID W20002100 A IDW20002100 A ID W20002100A ID 20002100 A ID20002100 A ID 20002100A ID 27002 A ID27002 A ID 27002A
Authority
ID
Indonesia
Prior art keywords
casasage
observers
casasage observers
Prior art date
Application number
IDW20002100A
Other languages
English (en)
Indonesian (id)
Inventor
Wannamaker Marion
Guy W Bemis
Paul S Charifson
David J Lauffer
Michael D Mullican
Keith P Wilson
James W Janetka
Robert J Davies
Anne-Laure Grillot
Zhan Shi
Cocnelia J Forster
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of ID27002A publication Critical patent/ID27002A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Crystallography & Structural Chemistry (AREA)
IDW20002100A 1998-03-19 1999-03-19 Penghambat-penghambat kaspase ID27002A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7877098P 1998-03-19 1998-03-19

Publications (1)

Publication Number Publication Date
ID27002A true ID27002A (id) 2001-02-22

Family

ID=22146109

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002100A ID27002A (id) 1998-03-19 1999-03-19 Penghambat-penghambat kaspase

Country Status (34)

Country Link
US (3) US6531474B1 (no)
EP (6) EP2261233A3 (no)
JP (3) JP4594520B2 (no)
KR (2) KR100928878B1 (no)
CN (1) CN1321129C (no)
AP (1) AP2000001919A0 (no)
AR (1) AR019011A1 (no)
AT (1) ATE410439T1 (no)
AU (1) AU769033B2 (no)
BG (1) BG104863A (no)
BR (2) BR9909660A (no)
CA (1) CA2324226C (no)
CZ (1) CZ302281B6 (no)
DE (1) DE69939689D1 (no)
DK (1) DK1064298T3 (no)
ES (1) ES2315010T3 (no)
GE (1) GEP20043163B (no)
HK (1) HK1035733A1 (no)
HU (1) HU227920B1 (no)
ID (1) ID27002A (no)
IL (3) IL138469A0 (no)
IS (1) IS5622A (no)
NO (1) NO331829B1 (no)
NZ (2) NZ506963A (no)
PL (1) PL204619B1 (no)
PT (1) PT1064298E (no)
RU (1) RU2274642C2 (no)
SI (1) SI1064298T1 (no)
SK (1) SK286736B6 (no)
TR (1) TR200103406T2 (no)
TW (1) TWI243828B (no)
UA (2) UA74133C2 (no)
WO (1) WO1999047545A2 (no)
ZA (1) ZA200004652B (no)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227920B1 (en) * 1998-03-19 2012-06-28 Vertex Pharma Inhibitors of caspases, pharmaceutical compositions comprising thereof and their use
US7157430B2 (en) 1998-10-22 2007-01-02 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases
US6242422B1 (en) * 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US6720415B2 (en) 1998-12-02 2004-04-13 Princeton University Compositions and methods for regulating bacterial pathogenesis
US7326542B2 (en) 1998-12-02 2008-02-05 Princeton University Compositions and methods for regulating bacterial pathogenesis
WO2001027085A1 (en) * 1999-10-13 2001-04-19 Merck Frosst Canada & Co. Nicotinyl aspartyl ketones as inhibitors of caspase-3
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6525024B1 (en) 2000-04-17 2003-02-25 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
US6559176B1 (en) 2000-05-10 2003-05-06 Princeton University Compounds and methods for regulating bacterial growth and pathogenesis
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
ATE510837T1 (de) * 2000-09-13 2011-06-15 Vertex Pharma Caspase inhibitoren und deren verwendung
US20030039661A1 (en) * 2001-03-02 2003-02-27 Teresa Aja Methods, compositions and kits for preserving antigenicity
US7364736B2 (en) 2001-06-26 2008-04-29 Amgen Inc. Antibodies to OPGL
US7410956B2 (en) * 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
WO2003075853A2 (en) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
FR2839309B1 (fr) 2002-05-03 2004-07-23 Aventis Pharma Sa Nouveaux derives de l'acide hexahydro-pyridazine-3- carboxylique, chimiotheques les contenant, leur utilisation comme medicaments, compositions pharmaceutiques les contenant et leurs procedes de preparation
US7001899B2 (en) 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
AU2003263393A1 (en) * 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
TWI289668B (en) 2002-09-06 2007-11-11 Amgen Inc Therapeutic human anti-IL-1R1 monoclonal antibody
AP2021A (en) 2002-10-23 2009-08-03 Glenmark Pharmaceuticals Ltd Novel tricyclic compounds useful for the treatmentof inflammatory and allergic disorders: Process f or their preparation and pharmaceutical compositions containing them
FR2846969A1 (fr) * 2002-11-08 2004-05-14 Salles Jean Pierre Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical
FR2847160A1 (fr) * 2002-11-20 2004-05-21 Oreal Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
AU2003295041A1 (en) * 2002-11-20 2004-06-18 L'oreal Composition for hair care or eyelashes containing a pyrazol-carboxamide, its use for stimulating hair and eyelash growth and/or for preventing loss thereof
NZ542882A (en) 2003-04-11 2007-10-26 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
AU2003902704A0 (en) * 2003-05-29 2003-06-19 Crc For Waste Management And Pollution Control Limited Of Unsw Process for producing a nanoscale zero-valent metal
WO2005117846A2 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
US20050233974A1 (en) * 2003-12-01 2005-10-20 John Randle Treating infectious diseases using ice inhibitors
DE60326150D1 (de) * 2003-12-12 2009-03-26 Straetmans Chemische Produkte Anisinsäure und Glyceride enthaltende Zusammensetzungen
AU2011226946B2 (en) * 2004-02-27 2012-05-03 Vertex Pharmaceuticals Incoporated Caspase Inhibitors and Uses Thereof
NZ549665A (en) 2004-02-27 2010-09-30 Vertex Pharma Caspase inhibitors and uses thereof
CA2820541A1 (en) * 2004-02-27 2005-09-15 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
HUE024556T2 (hu) * 2004-03-12 2016-02-29 Vertex Pharma Eljárások és intermedierek aszparagin acetál kapszáz inhibitorok elõállítására
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2005112633A2 (en) * 2004-05-14 2005-12-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20060128696A1 (en) * 2004-05-15 2006-06-15 Annamaria Vezzani Treating seizures using ice inhibitors
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006017295A2 (en) * 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
DE602005008622D1 (de) * 2004-09-17 2008-09-11 Biomas Ltd Neue tellurium-verbindungen und ihre verwendung als immunmodulatoren
MX2007004400A (es) 2004-10-13 2007-06-19 Glenmark Pharmaceuticals Sa Procedimiento para la preparacion de n-(3,5-dicloropirid-a-il)-4- ifluorometoxi-8-metanosulfonamido-dibenzo [b,d] difuran-1-carboxamida.
PL1831227T3 (pl) 2004-12-17 2013-10-31 Glenmark Pharmaceuticals Sa Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych
PT1831227E (pt) 2004-12-17 2013-08-23 Glenmark Pharmaceuticals Sa Proteínas buganina modificadas, citotoxinas e métodos e utilizações das mesmas
JP4673068B2 (ja) * 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
DE102005017116A1 (de) * 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
WO2007015931A2 (en) * 2005-07-28 2007-02-08 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
JP2009542689A (ja) * 2006-07-07 2009-12-03 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 選択的カスパーゼ阻害剤
EP2099454A4 (en) * 2006-11-17 2010-11-10 Abbott Lab AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
US8618663B2 (en) 2007-09-20 2013-12-31 International Business Machines Corporation Patternable dielectric film structure with improved lithography and method of fabricating same
US7709370B2 (en) 2007-09-20 2010-05-04 International Business Machines Corporation Spin-on antireflective coating for integration of patternable dielectric materials and interconnect structures
US8084862B2 (en) * 2007-09-20 2011-12-27 International Business Machines Corporation Interconnect structures with patternable low-k dielectrics and method of fabricating same
WO2009124265A1 (en) * 2008-04-03 2009-10-08 The Board Of Trustees Of The Leland Stanford Junior University Probes for in vivo targeting of active cysteine proteases
AU2009252995A1 (en) * 2008-05-27 2009-12-03 Imperial Innovations Limited Process for producing porous scaffolds from sinterable glass
US20110152343A1 (en) * 2009-12-22 2011-06-23 Functional Genetics, Inc. Protease inhibitors and broad-spectrum antiviral
GB201001070D0 (en) 2010-01-22 2010-03-10 St George's Hospital Medical School Theraputic compounds and their use
WO2011094426A1 (en) * 2010-01-29 2011-08-04 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Caspase inhibitors
GB201011411D0 (en) 2010-07-06 2010-08-18 St Georges Hosp Medical School Therapeutic compounds and their use
JP6006908B2 (ja) 2010-11-05 2016-10-12 ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ Ｉｃｅ阻害化合物およびその使用
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
MY165742A (en) 2011-10-14 2018-04-23 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2013055984A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
CN103987696B (zh) 2011-10-14 2016-12-21 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
CA2882088C (en) 2012-08-23 2021-11-23 Alios Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
JP6154473B2 (ja) 2012-10-12 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ＸＩａ因子阻害剤の結晶形
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
NO2760821T3 (no) 2014-01-31 2018-03-10
EP3988549A1 (en) 2014-01-31 2022-04-27 Bristol-Myers Squibb Company Macrocycles with heterocyclic p2' groups as factor xia inhibitors
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
US10081623B2 (en) 2014-09-04 2018-09-25 Bristol-Myers Squibb Company Diamide macrocycles that are FXIa inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
US10550070B2 (en) 2015-09-17 2020-02-04 City Of Hope PCNA inhibitors
EP3459941A4 (en) 2016-07-22 2020-02-19 Kissei Pharmaceutical Co., Ltd. pyrrolidine
PL3558335T3 (pl) 2016-12-23 2023-08-21 Casp-Aid Inc. Inhibicja kaspazy-1 i jej zastosowanie w zapobieganiu i leczeniu schorzeń neurologicznych
EP3836954A1 (en) 2018-08-13 2021-06-23 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
US20230404972A1 (en) * 2020-11-25 2023-12-21 Lysosomal and Rare Disorders Research and Treatment Center, Inc. Inhibition of caspase pathway as a treatment for lysosomal storage disorders

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2973111A (en) * 1958-02-11 1961-02-28 Dempster Brothers Inc Compaction bodies
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US4465679A (en) 1983-01-31 1984-08-14 Usv Pharmaceutical Corporation 1,2-Diaza-3-one compounds, their use in treating hypertension and pharmaceutical compositions thereof
IL72523A (en) 1983-08-12 1988-06-30 Takeda Chemical Industries Ltd 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives,their production and pharmaceutical compositions containing them
US5055451A (en) 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
US5158936A (en) 1986-12-22 1992-10-27 Syntex (U.S.A.) Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
US5008245A (en) 1988-10-27 1991-04-16 University Of Kentucky Research Foundation Novel peptidyl carbamate inhibitors of the enzyme elastase
CA2021660A1 (en) 1989-07-26 1991-01-27 Philippe Bey Peptidase inhibitors
NZ235155A (en) 1989-09-11 1993-04-28 Merrell Dow Pharma Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
US5416013A (en) 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
AU7775991A (en) 1990-04-04 1991-10-30 Immunex Corporation Interleukin 1beta protease
ES2124710T3 (es) 1991-03-15 1999-02-16 Hoechst Ag Procedimiento para el acoplamiento pinacolinico reductor diastereoselectivo de alfa-aminoaldehidos homoquirales.
CA2071674C (en) * 1991-06-21 2003-08-19 Kevin T. Chapman Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
JP3190431B2 (ja) 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
US5278061A (en) 1991-08-16 1994-01-11 Merck & Co., Inc. Affinity chromatography matrix useful in purifying interleukin-1β converting enzyme
EP0533226A3 (en) 1991-08-16 1993-08-18 Merck & Co. Inc. Novel chromophore containing compounds
US6348570B1 (en) 1991-08-16 2002-02-19 Merck & Co., Inc. Chromophore containing compounds and their use in determining interleukin-1β convertase activity
EP0533350B1 (en) 1991-08-16 1999-05-26 Merck & Co. Inc. DNA encoding precursor interleukin 1B converting enzyme
AU657701B2 (en) 1991-08-30 1995-03-23 Vertex Pharmaceuticals Incorporated Interleukin 1beta protease and interleukin 1beta protease inhibitors
ATE140449T1 (de) 1991-10-07 1996-08-15 Hoechst Ag Verfahren zur diastereoselektiven reduktiven pinakol-kupplung von homochiralen alpha- aminoaldehyden
GB9123326D0 (en) 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
AU1339092A (en) 1991-12-13 1993-07-19 Corvas International, Inc. Reagents for automated synthesis of peptide analogs
EP0547699A1 (en) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
AU3479593A (en) 1992-01-31 1993-09-01 Merck & Co., Inc. Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
ATE169224T1 (de) 1992-02-21 1998-08-15 Merck & Co Inc Peptidylderivate und inhibitoren des interleukin- 1-g(b)-konvertierenden enzyms
JPH08500242A (ja) 1992-06-24 1996-01-16 メルク エンド カンパニー インコーポレーテッド インターロイキン１β前駆体の転換酵素をコードするＤＮＡ
DK0654041T3 (da) 1992-07-31 1998-10-26 Pfizer Peptidyl-4-amino-2,2-difluor-3-oxo-1,6-hexandisyre-derivater som anto-inflammatoriske midler
CA2109646C (en) 1992-11-24 2000-03-07 Gaston O. Daumy Para-nitroanilide peptides
EP0618223A3 (en) 1993-03-08 1996-06-12 Sandoz Ltd Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents.
TW494094B (en) 1993-04-29 2002-07-11 Vertex Pharma Peptide analogs as irreversible interleukin-1β protease inhibitors and pharmaceutical compositions comprising the same
US5462939A (en) 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
US5411985A (en) 1993-05-17 1995-05-02 Merck & Co., Inc. Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme
JPH0789951A (ja) 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
JPH0725887A (ja) 1993-06-04 1995-01-27 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
CA2165777A1 (en) 1993-06-24 1995-01-05 Junying Yuan Programmed cell death genes and proteins
US5866545A (en) 1993-08-13 1999-02-02 Merck & Co., Inc. Substituted ketone derivatives as inhibitors of interleukin-1β converting enzyme
DK0653417T3 (da) * 1993-11-11 1998-03-30 Basf Ag P-Hydroxyanilinderivater, fremgangsmåde til deres fremstilling og deres anvendelse til bekæmpelse af skadelige svampe eller skadedyr
US5714484A (en) 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
CN1118458C (zh) 1994-03-31 2003-08-20 弗特克斯药品有限公司 作为白细胞介素抑制剂的嘧啶基衍生物
WO1995029672A1 (en) 1994-04-29 1995-11-09 Sanofi Winthrop, Inc. HALOMETHYL AMIDES AS IL-1β PROTEASE INHIBITORS
US5492824A (en) 1994-05-12 1996-02-20 Basf Ag Ice and ice-like compositions and methods of making same
US5552400A (en) 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US6057119A (en) 1994-06-17 2000-05-02 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
GB2292149A (en) * 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
US5498616A (en) 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
TW394764B (en) 1995-02-14 2000-06-21 Mitsubishi Chemcal Corp Oxygen-containing heterocyclic derivatives
EP0820464A2 (en) 1995-03-31 1998-01-28 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
JPH09165360A (ja) * 1995-03-31 1997-06-24 Takeda Chem Ind Ltd システインプロテアーゼ阻害剤
US5798442A (en) 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
WO1997007805A1 (en) 1995-08-31 1997-03-06 Smithkline Beecham Corporation Interleukin converting enzyme and apoptosis
WO1997008174A1 (en) 1995-08-31 1997-03-06 Smithkline Beecham Corporation Interleukin converting enzyme and apoptosis
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US6136834A (en) * 1995-12-27 2000-10-24 Ono Pharmaceutical Co., Ltd. Tetrazole compounds and pharmaceutical agents containing such derivative
AU3359697A (en) 1996-07-08 1998-02-02 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
WO1998004539A1 (fr) 1996-07-29 1998-02-05 Mitsubishi Chemical Corporation Derives heterocycliques oxygenes
DE69718012T2 (de) * 1996-09-12 2003-09-25 Idun Pharmaceuticals Inc C-terminale modifizierte (n-substituierte)-2-indolyl dipeptide als inhibitoren von der ice/ced-3 cysteinprotease familie
NZ330451A (no) 1996-09-12 2000-01-28 Idun Pharmaceuticals Inc
US5869519A (en) * 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
DE69734718T2 (de) 1996-09-12 2006-08-24 Idun Pharmaceuticals, Inc., San Diego Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
US5968927A (en) * 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US6184244B1 (en) * 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
HUP9700816A3 (en) 1997-04-28 1999-06-28 Gyogyszerkutato Intezet 3(r)-3-amino-4-carboxy-butiraldehyde derivatives inhibiting release of interleukin-1-beta
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
EP1024721B1 (en) * 1997-10-31 2004-09-15 Kimberly-Clark Worldwide, Inc. Creped nonwoven materials and liner
HU227920B1 (en) * 1998-03-19 2012-06-28 Vertex Pharma Inhibitors of caspases, pharmaceutical compositions comprising thereof and their use
US6197750B1 (en) * 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6242422B1 (en) * 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
US20050209162A1 (en) * 2003-11-10 2005-09-22 Amit Roy Methods for monitoring IL-18
WO2005117846A2 (en) * 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
NZ549665A (en) * 2004-02-27 2010-09-30 Vertex Pharma Caspase inhibitors and uses thereof

Also Published As

Publication number Publication date
EP2261234A3 (en) 2011-04-20
NO20004546D0 (no) 2000-09-12
HUP0103575A2 (hu) 2002-02-28
SI1064298T1 (sl) 2009-02-28
UA74133C2 (uk) 2005-11-15
JP2010241822A (ja) 2010-10-28
PT1064298E (pt) 2009-01-02
SK286736B6 (sk) 2009-04-06
EP2011800A2 (en) 2009-01-07
CN1323314A (zh) 2001-11-21
NZ506963A (en) 2003-10-31
UA96113C2 (en) 2011-10-10
EP2261234A2 (en) 2010-12-15
CA2324226C (en) 2012-06-05
BG104863A (en) 2001-04-30
EP1064298B1 (en) 2008-10-08
EP2261232A2 (en) 2010-12-15
NZ528282A (en) 2005-05-27
EP2261235A2 (en) 2010-12-15
DK1064298T3 (da) 2009-01-19
US8691848B2 (en) 2014-04-08
IL138469A (en) 2010-11-30
RU2274642C2 (ru) 2006-04-20
NO20004546L (no) 2000-11-09
GEP20043163B (en) 2004-01-26
CZ20003409A3 (cs) 2001-01-17
ZA200004652B (en) 2002-04-24
DE69939689D1 (de) 2008-11-20
EP2011800A3 (en) 2009-06-24
EP2261233A2 (en) 2010-12-15
HUP0103575A3 (en) 2002-10-28
HK1035733A1 (en) 2001-12-07
US6531474B1 (en) 2003-03-11
KR20010042038A (ko) 2001-05-25
US7358273B2 (en) 2008-04-15
JP2002506878A (ja) 2002-03-05
BR9909660A (pt) 2000-11-21
ES2315010T3 (es) 2009-03-16
WO1999047545A3 (en) 1999-11-25
CA2324226A1 (en) 1999-09-23
IL138469A0 (en) 2001-10-31
EP2261235A3 (en) 2011-04-20
CN1321129C (zh) 2007-06-13
TR200103406T2 (tr) 2002-06-21
EP2261233A3 (en) 2011-04-20
IS5622A (is) 2000-09-08
JP4594520B2 (ja) 2010-12-08
KR20080020703A (ko) 2008-03-05
AR019011A1 (es) 2001-12-26
EP2261232A3 (en) 2011-04-20
BRPI9909660B8 (pt) 2021-05-25
PL204619B1 (pl) 2010-01-29
EP1064298A2 (en) 2001-01-03
AU3098699A (en) 1999-10-11
BRPI9909660B1 (pt) 2018-09-18
HU227920B1 (en) 2012-06-28
TWI243828B (en) 2005-11-21
AP2000001919A0 (en) 2000-09-30
CZ302281B6 (cs) 2011-01-26
WO1999047545A2 (en) 1999-09-23
US20090048226A1 (en) 2009-02-19
KR100928878B1 (ko) 2009-11-30
AU769033B2 (en) 2004-01-15
PL343611A1 (en) 2001-08-27
NO331829B1 (no) 2012-04-16
IL206621A0 (en) 2010-12-30
JP2006206600A (ja) 2006-08-10
ATE410439T1 (de) 2008-10-15
US20030232986A1 (en) 2003-12-18
SK13822000A3 (sk) 2001-04-09
KR100898094B1 (ko) 2009-05-18

Similar Documents

Publication Publication Date Title
ID27002A (id) Penghambat-penghambat kaspase
ATE341990T1 (de) Sigmidoskop
DE59911453D1 (de) Aktivkohlefilter
FI980450A0 (fi) Foerfarande foer att framstaella en fettblandning
DE59901560D1 (de) Retrograder tibianagel
DE59902874D1 (de) Buchsenkontakt
DE59907306D1 (de) Fadenchangierung
ID23458A (id) Bentuk sediaan nefazodon
DE59911683D1 (de) Fahrzeugschliessanlage
FI980229A0 (fi) Foerfarande foer att behandla en trafikkanalbegaeran
ATE262513T1 (de) Benzoylpyridazine
DE59903966D1 (de) Exzenterzahnradgetriebe
DE59908769D1 (de) N-arylsulfonyl-aminosäure-omega-amide
DE59903106D1 (de) Tripode-gleichlaufdrehgelenk
ID27022A (id) Penghambat-penghambat fkbp
DE59908057D1 (de) Underdruckhandhabungseinrichung
DE59901046D1 (de) Methylcyclotetradec-5-en-1-one
DE59807217D1 (de) Nadellager
DE1118098T1 (de) Mehrfachflussigelektrosprühschnittstelle
DE59808995D1 (de) Endomikroskopsystem
DE19842103B4 (de) Stanznietzuführung
DE59903616D1 (de) Rollenwicklerwalze
DE59902088D1 (de) Achrathermer Reimager
DE59900612D1 (de) Dispersionsazofarbstoffmischungen
FI980619A0 (fi) Foerfarande foer att minska NOx-foereningar i en sodapannas roekgaser